title: Effects of local intracoronary paclitaxel delivery using the Remedy transport catheter on neointimal hyperplasia after stent implantation in a porcine model.
abstract: OBJECTIVE
  To assess the effects of local paclitaxel delivery using the Remedy catheter on neointimal hyperplasia in a porcine model and compare these results to commercially available BMS and biodegradable polymer-coated paclitaxel-eluting stents (BP-PES).
  
  
  METHODS
  A total of 31 stents were implanted into coronary arteries of 15 domestic swine including eight BMS, six BP-PES, and 17 BMS after intravasal paclitaxel delivery at doses of 250 μg (LPD250; n=9) and 500 μg (LPD500, n=6). All stents were implanted under quantitative coronary angiography (QCA) guidance to achieve a balloon/artery diameter ratio of 1.15:1.0. Twenty-eight days after the procedure, follow-up coronary angiography was performed, the animals were euthanized, and the coronary arteries harvested for histopathological analysis.
  
  
  RESULTS
  At follow-up, QCA analysis revealed that lumen loss was significantly worse in BMS and in both LPD groups in comparison to BP-PES stents (P=.02). Histomorphometric analysis showed that the LPD500 group presented the highest percentage of area stenosis, achieving a statistically significant difference in comparison to BMS and BP-PES stents.
  
  
  CONCLUSIONS
  Our study demonstrates that local paclitaxel delivery using the Remedy transport catheter in the two studied doses (250 and 500 μg) is not effective at neointimal hyperplasia inhibition.
authors.affiliation: Upper-Silesian Center of Cardiology, Medical University of Silesia, Katowice, Poland. kmilewski@crf.org
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Milewski
authors.forename: Aleksander
authors.initials: A
authors.lastname: Zurakowski
authors.forename: Jacek
authors.initials: J
authors.lastname: Pajak
authors.forename: Lukasz
authors.initials: L
authors.lastname: Liszka
authors.forename: Marcin
authors.initials: M
authors.lastname: Debinski
authors.forename: Piotr P
authors.initials: PP
authors.lastname: Buszman
authors.forename: Motaz Abu
authors.initials: MA
authors.lastname: Samra
authors.forename: Piotr
authors.initials: P
authors.lastname: Dominek
authors.forename: Michael S
authors.initials: MS
authors.lastname: Aboodi
authors.forename: Grzegorz L
authors.initials: GL
authors.lastname: Kaluza
authors.forename: Pawel
authors.initials: P
authors.lastname: Buszman
mesh_terms: D000818:Animals; D062906:Cardiac Catheters; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D049109:Cell Proliferation / Q000187:drug effects; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects*; D054855:Drug-Eluting Stents; D006965:Hyperplasia; D023421:Models, Animal; D058426:Neointima; D017239:Paclitaxel / Q000008:administration & dosage*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation*; D011474:Prosthesis Design; D034421:Sus scrofa; D013997:Time Factors
chemical_list: D002317:Cardiovascular Agents; D017239:Paclitaxel